These results mean patients whose Radscores were low but had a high expression of CDK1, PBK, and CHEK1 had a poor prognosis, signifying the significance of these oncogenes in the cell cycle and their potential to be prognostic biomarkers in GBM. The gene discussed is CHEK1; the disease is glioblastoma.